



Pharmacology of Quinolones & sulphonamides

Dr. Nashwa Abo-Rayah

*Associate prof. (clinical & experimental
pharmacology)*



Mu'tah University- Faculty of Medicine

2023/2024

- ✓ Synthetic antimicrobials
- ✓ Bactericidal
- ✓ Primarily gram-negative bacteria

Nalidixic acid


- **First member: prototype**
- **Advantages:**
 - **1- Cover G-ve bacteria**
 - **2- Rapidly excreted in urine in concentrations enough for treatment of UTIs**

❖ Disadvantages of nalidixic acid

- ❖ Concentration of free drug in plasma & most tissues is **non-therapeutic** for **systemic infections**
- ❖ Narrow spectrum
- ❖ Rapid development of bacterial **resistance**.
- ❖ So:
 - ❖ **Limited therapeutic use**

Fluoroquinolones

- Quinolones are molecules **structurally derived from the heterobicyclic aromatic compound quinoline.**
- **Fluorination** of quinolone structure at position 6 resulted in derivatives called **fluoroquinolones**



generation 0	1st generation	2nd generation	3rd generation	4th generation
--------------	----------------	----------------	----------------	----------------

no clinical use	mostly not in use	most of the introduced molecules remain in use		
-----------------	-------------------	--	--	--

Gram spectrum				
-	-	- and some +	- and more +	- and many+

potency →				
-----------	--	--	--	--

Advantages of quinolones

- ❖ High potency
- ❖ Expanded spectrum/Broad antimicrobial activity
- ❖ Slow development of resistance
- ❖ Better tissue penetration
- ❖ Prolonged duration of action
- ❖ Used for wide variety of infectious diseases

Generation	1st	2nd	3rd	4th
	Nalidixic acid	Norfloxacin, ciprofloxacin	Levofloxacin	Moxifloxacin, Gemifloxacin
Spectrum	Only some G- ve	More G-ve	<ul style="list-style-type: none"> • Both G-ve and G+ve • Atypical bacteria 	<ul style="list-style-type: none"> • Both G-ve and G+ve • Atypical bacteria • Anaerobic bacteria
Duration of action	0	3hs, 8hs	12hs	24hs
Potency	+	++	+++	++++

Pks

- **Key:** MW less than 500, chemical structure has no –OH groups
- **Absorption:**
 - Rapid and complete **oral** absorption, avoid with food containing Al, Ca, Iron
- **Distribution:**
 - High tissue penetration: Concentration in lung, sputum, muscle, bone, cartilage (minerals), prostate, and phagocytes & neutrophils (IC) exceeds that in plasma
 - Can pass BBB: attain concentrations to treat CNS infections
 - Pass placental barrier: teratogenic
 - Excreted in breast milk
- **Metabolism:** liver
- **Excretion:** in urine unchanged : **Urinary** are 10-50-fold higher than in plasma: UTIs
- **Moxifloxacin** excreted by non-renal routes: not used in UTIs

Mechanism of action

Quinolones target **bacterial** DNA gyrase & Topoisomerase IV

- Gram negative bacteria - DNA Gyrase

- Gram positive bacteria - Topoisomerase IV

- In mammalian cells(human cells) **Topoisomerase II**


- 1- Low affinity for flouoroquinolones

- 2- Inhibited by quinolones only at much higher concentrations.

Low toxicity to host cells

Mechanism of action

- Double helical DNA
- Two strands must separate to permit DNA replication / transcription
- “over winding” / excessive positive supercoiling of DNA leads to faulty protein synthesis and bacterial death.



Mechanism of resistance

- **Chromosomal mutation**

bacteria produce DNA Gyrase/ Topoisomerase IV with **reduced affinity** for quinolones.



- **Efflux** of these drugs across bacterial membranes

- Resistance is **slow** to develop

THERAPEUTIC USES

1- Urinary tract infections

- Most commonly used antimicrobials for UTI
- Very effective against **Gram negative bacilli** like

E.coli

Proteus

Enterobacter

Psuedomonas

Ciprofloxacin 500 mg bd

2- **Salmonella typhi infection (typhoid fever)**

- **Ciprofloxacin 500 mg bd x 10 days**
- Prevents carrier state also

3- Respiratory infections:

- Pneumonia
- Acute sinusitis
- Chr. Bronchitis
- Respiratory quinolones: levofloxacin, moxifloxacin, Gemifloxacin

They are distributed IC in macropgages and polymorphs

Cover G+ve and atypical bacteria

4-Bone and joint infections: Osteomyelitis & joint infections

➤ **5- Meningitis**

➤ **6- - Atypical infections**

Adverse effects

1- Musculoskeletal:

- **Tendonitis & tendon rupture:** ciprofloxacin: tendinopathy of Tendo Achillis

- **Arthropathy (Joint disease)** in immature animals,


 - Use in children less than 6-12 years, pregnancy and during breast feeding contraindicated

- **2- CNS:** excitation due to blocking of GABA receptors: **seizures** have occurred predominantly in patients receiving **theophylline** or a **NSAIDs** and **epilepsy patients**


- **3- QT interval prolongation:** trovafloxacin withdrawn in 2016.
- Cautious use in patients who are taking drugs that are known to prolong the QT interval
- **tricyclic antidepressants**
- **Phenothiazine**
- **class I anti-arrhythmics**
- **4- drug interactions:**
- **NSAIDs & theophylline** may enhance CNS toxicity of FQ's
 - Seizures reported
- **Antacids, Sucralfate, Iron salts**
reduce absorption of FQ,s
- Quinolones are cytochrome p450 inhibitors

Inhibitors of synthesis of essential metabolites

- Antimicrobials in this class;
- • Sulfonamides • Trimethoprim
- Bacteriostatic



P-amino-benzoic acid (PABA)




Sulfanilamide

PKs


- **Example: sulphadiazine**
- **Absorption:** good oral absorption, not affected by food
- **Distribution:**
- BBB: pass: used with penicillin for treatment of bacterial meningitis in 1930s-1940s
- Used now for treatment of CNS toxoplasmosis and plasmodium falciparum
- Good tissue penetration: prostate
- Placenta: pass and excreted in breast milk
- **Metabolism:** liver
- **Excretion:** renal: acylated but active metabolite (UTIs, alkalinization of urine)

PDs

- Competitive inhibitors of **dihydrofolate synthase** bacterial enzyme responsible for the incorporation of **PABA** into dihydrofolic acid (immediate precursor of folic acid).
- Folic acid required for synthesis of purines and nucleic acid
- Sulfonamides mimic P-aminobenzoic acid (PABA)



P-amino-benzoic acid (PABA)



Sulfanilamide

P-Aminobenzoic acid

Dihydropteroate synthase

Sulfonamide


Dihydrofolic acid or Dihydrofolate

Dihydrofolate reductase

Trimethoprim

Tetrahydrofolic acid

DNA



CO-TRIMOXAZOLE

- **Sulfamethoxazole** with **trimethoprim** in 5: 1
- Tablets contain 400 mg of sulfamethoxazole plus 80 mg of trimethoprim.
- Trimetoprim inhibits the enzyme dihydrofolic acid reductase (sequential block)
- Bacteriostatic activity.
- **Spectrum:**
- Some G+ve: streptococcal tonsillitis, pharyngitis
- Some G-ve: E.coli: UTIs
- Atypical bacteria: chlamydia: eye, genital
- Toxoplasma
- Plasmodium falciparum
- **Pneumocystis carinii**

Indications of co-trimoxazole

- 1- UTIs: excreted in high concentration in urine (alkalinization of urine)
- 2- Streptococcal pharyngitis, tonsillitis
- 3- AIDS: PCP: **Pneumocystis carinii** (drug of choice)
- 4- **toxoplasmosis of CNS**

Other sulphonamides combinations

Silver Sulfadiazine (cream)

- Inhibits growth of nearly all pathogenic **bacteria (psudomonus) & fungi**
- Used topically to reduce incidence of infections of wounds from **burns**
 - Slowly releases silver ions -antimicrobial action
 - Sulphadoxine & pyrimethamine: malignant malaria (plasmodium falciparum): sequential block
 - Sulphasalazine: sulphapyridine & **5-aminosalicylic acid: ulcerative colitis**

Adverse effects


- 1- **Allergy**: skin rash: common
- Stevens-Johnson syndrome (SJS) (TEN: toxic epidermal necrolysis): rare
- 2- **Crystalluria**
- Insoluble in acidic urine
- Precipitate, forming crystalline deposits that can cause urinary obstruction
- Fluid intake sufficient to ensure a daily urine volume of at least 1200ml
- Alkalinization of the urine

3- kernicterus

- Administration to **newborn infants esp. premature**
 - Sulfonamides displace bilirubin (jaundice) from plasma albumin.
 - Free bilirubin is deposited in basal ganglia & sub-thalamic nuclei of the brain causing an encephalopathy & permanent brain damage called **kernicterus**.

- **4- anemia:**
- Hemolytic anemia: G6PD deficiency
- Megaloblastic anemia: treated by folic acid tab. 5 mg once daily
- **5- during pregnancy:**
- 1st trimester: neural tube defect (spina bifida): teratogenic
- 3rd trimester: kernicterus
- **Contraindications:** pregnancy, children less than 2 y, allergy to sulpha, favusism, renal stones

Spina Bifida (Open Defect)



THANK YOU